WO2002004002A2 - Verwendung von stämmen des parapoxvirus ovis zur herstellung von antiviralen arzneimitteln und arzneimitteln gegen krebs - Google Patents
Verwendung von stämmen des parapoxvirus ovis zur herstellung von antiviralen arzneimitteln und arzneimitteln gegen krebs Download PDFInfo
- Publication number
- WO2002004002A2 WO2002004002A2 PCT/EP2001/007991 EP0107991W WO0204002A2 WO 2002004002 A2 WO2002004002 A2 WO 2002004002A2 EP 0107991 W EP0107991 W EP 0107991W WO 0204002 A2 WO0204002 A2 WO 0204002A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- strains
- medicaments
- pharmaceutical preparations
- cells
- infection
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24211—Parapoxvirus, e.g. Orf virus
- C12N2710/24232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Definitions
- the present invention relates to the use of strains of the Parapoxvirus ovis as an immunotherapeutic in immunodeficiency of infectious or non-infectious
- the present invention further relates to the use of strains of the Parapoxvirus ovis and medicinal forms produced therefrom as immunotherapeutic agents or immunoprophylactic agents, in stress metaphylaxis for the prevention or prevention of infectious diseases after stress (for example operations); the use in infection prophylaxis to prevent or prevent infectious diseases by administering before surgery or surgery (eg before implantation of prostheses or before dental surgery), the use in infection prevention or therapy of acute or chronic viral infections, for example of the respiratory tract, papillomavirus infections , infection with He ⁇ esviren, HIV infection, virus infection of internal organs such as infection with hepatitis viruses, the use in wound healing to accelerate wound healing processes and the use to support the healing of poorly or non-healing wounds (eg ulcus cruris), the Use in diseases such as multiple sclerosis / asthma, warts and other forms of new skin, use in diseases of the allergic type, use to prevent the outbreak of systemic allergies and use in topical all rgien and the use to improve well-
- Descendants of these strains or parts or fragments of viruses of these strains or these descendants obtained by passage and / or adaptation to specific cells, for example WI-38, MRC-5 or Vero cells, can also be used.
- Parts are to be understood as meaning genomic or subgenomic fragments expressed by means of suitable vectors, for example vaccinia, in suitable systems, for example fibroblast cell cultures. Fragments are understood to mean the fractions obtained by biochemical purification, for example by chromatography, physically, for example by exposure to ultrasound, of disrupted particles.
- the present invention further relates to the use of said strains of parapoxvirus ovis for the production of medicaments and pharmaceutical preparations. Furthermore, the invention relates to the use of said strains of parapoxvirus ovis in combination with other agents for the production of medicaments and pharmaceutical preparations for antiviral or cancer therapy.
- latent and chronically persistent viral infections can be activated or reactivated by immunosuppression, or vice versa, that the immune system suppresses (eg recurs) the acute disease that can be caused by a virus that is latent a latent He ⁇ esvirus infection with immunosuppression: lip sores with stress or cortisone). It is also known that chronic persistent and latent viral infections are difficult or impossible to treat with conventional antiviral substances on a low molecular weight basis.
- viral enzymatic activity in such infections for example the lack of viral polymerase activity which must first incorporate a nucleoside inhibitor into the viral nucleic acid so that it can lead to chain termination in the viral DNA, for example; the lack of a viral thymidine kinase activity, which, for example, must first phosphorylate an antiviral compound so that it can become active
- the lack of recognition infection of infected or degenerate cells for example cancer cells or viral antigens, by the host's immune system.
- Paramunity inducers consist, for example, of chemically inactivated parapoxvirus ovis, Strain D 1701 (DE 3 504 940) this virus (Parapoxvirus ovis, Strain D 1701) is a product manufactured
- the inactivated parapoxvirus induces non-specific protection against infections with a wide variety of pathogens in animals. It is believed that this protection is conveyed through various mechanisms of the organism's own defense system.
- the task therefore arises to further improve the therapeutic usability of the excellent action of parapoxvirus ovis in such a way that the generalized so-called induction of a paraspecific immune response of the parapoxvirus ovis, strain D 1701 described above is qualitatively increased and improved by use lower doses better antiviral or anti-tumor effects can be achieved. This would also lead to the expectation of a therapeutic effect with fewer side effects.
- the object of the invention was therefore to improve the immunological effect of the parapoxvirus.
- the object is achieved by using the above-mentioned strains of parapoxvirus ovis instead of the conventionally used strain D 1701.
- the present invention relates to the use of viruses which belong taxonomically to one of the strains NZ2, NZ-7, NZ-10 or orf-11 of Parapoxvirus ovis, for the production of medicaments for viral infections and cancer in humans and animals.
- the invention relates to the use of by passage or adaptation to suitable cell systems such as, for example, human cells such as WI-38, MRC-5, monkey cells, e.g. Vero cells, bovine cells such as e.g. BK-K13A47 / Reg or MDBK, and ovine cells such as MDOK
- suitable cell systems such as, for example, human cells such as WI-38, MRC-5, monkey cells, e.g. Vero cells, bovine cells such as e.g. BK-K13A47 / Reg or MDBK, and ovine cells such as MDOK
- a preferred object of the invention is the use of one of the
- parapoxvirus ovis NZ-2 mentioned here as an example was deposited on July 10, 2001 with the European Collection of Cell Cultures, Center for Applied Microbiology and Research, Porton Down, Salisbury, Wiltshire, SP4 0JG, United Kingdom.
- accession number is
- the concentration of the viruses was carried out as follows: 500 ml of supernatant from parapoxvirus ovis, strain NZ 2 (titer approx. 2x10 5 TCID 50 / ml) and parapoxvirus ovis, strain D 1701 (titer lxlO 7 TCID 50 / ml) were added to the same Virus titer set. A Beckmann ultracentrifuge (rotor SW28 at 28000 RPM 3 hours 4 ° C) was used for this. After centrifugation, the pellet with corresponding volumes dilution medium to a titer of lxl 0 7 TCID 50 were / ml adjusted.
- RNAse A Qiagen, Hilden
- the CDP-Star® system (Boehringer Mannheim) was used for immunological detection in accordance with the manufacturer's instructions.
- a Lumilmager® (Boehringer Mannheim) was used for the evaluation. The quantification
- HBV-specific DNA in the blood was carried out by means of quantitative PCR. First the plasma was obtained by centrifugation of the EDTA blood. The DNA was purified using the HighPure 16 System Viral Nucleic Acid Kit (Boehringer Mannheim) and examined for HB V-specific signals by quantitative PCR with the ABI PRISM TM 7700 Sequence Detection System (PE Applied Biosystems).
- ayw-570f (sense) 5 '- CTGTACCAAACCTTCGGACGG - 3' ayw-670r (antisense) 5 '- AGGAGAAACGGGCTGAGGC - 3 probe: ayw-613t 5 - CCATCATCCTGGGCTTTCGGAAAATT - 3 ⁇
- the DNA was amplified in 50 ul reaction volume (the reaction contained
- a histochemical analysis was carried out using antibodies against the hepatitis B virus core antigen (Dako). For this, parts of a liver lobe were fixed in 4% formaldehyde overnight, embedded in paraffin and cut (5 ⁇ m). After dewaxing and rehydration, the endogenous peroxidase activity was reduced to 3%
- the immune response was visualized with 3.3 diaminobenzidine tetrachloride and hydrogen peroxide.
- the sections were counterstained hematoxylin / eosin.
- Parapoxvirus ovis induce the complex capacity of the immune system to a strength that differs significantly from the potency of the previously known paramunity inducers.
- FIG 1 shows results of the treatment of HBV transgenic mice with strain
- HBV-specific DNA is significantly reduced in the liver in all dose groups in both strains compared to the placebo group, but more by Strain NZ 2. At the two lowest NZ 2 doses there is a significantly greater reduction in HBV-specific DNA than with the equivalent D 1701 dose groups.
- Figure 2 shows the result of the treatment of HBV transgenic mice with Strain D 1701 or NZ 2 in plasma. HBV-specific DNA is significantly reduced in plasma in all dose groups in both strains compared to the placebo group, but more by Strain NZ 2. In contrast to the lowest NZ 2 dose, the lowest dose of Strain D 1701 is no longer significantly antiviral.
- mice 7-8 weeks old Female Balb / c mice 7-8 weeks old were kept under sterile conditions and used for the experiment. The animals were randomized and grouped divided with 6 animals each. The following treatment regimen was used:
- Group 2 Parapoxvirus ovis strain D 1701; 5xl0 4 TCID 50 / dose
- Group 3 Parapoxvirus ovis strain NZ 2; 5x10 4 TCID 50 / dose
- Group 5 Parapoxvirus ovis strain D 1701; 5x10 4 TCID 50 / dose
- Group 6 Parapoxvirus ovis strain NZ 2; 5x10 4 TCID 50 / dose
- the application volume was 10 ml / kg, the application was intraperitoneal.
- peritoneal cells were concentrated using a centrifugation step (5 min at 3000 ⁇ m at room temperature in an Eppendorf table centrifuge), then in 0.2 ml lysis buffer (lysis solution: 25 mM sodium citrate, 4 M guanidium isothioeyanate, 0. 5% N-lauroyl sarcosine), shock-frozen and stored at -75 ° C until the RNA preparation.
- lysis buffer 25 mM sodium citrate, 4 M guanidium isothioeyanate, 0. 5% N-lauroyl sarcosine
- the total RNA was prepared by means of acidic phenol / chloroform extraction.
- the samples frozen in lysis buffer were thawed at room temperature and the following solutions were added for extraction: 1/10 lysis buffer volume 2 m sodium acetate (pH 4.0), 1 lysis buffer volume water-saturated phenol, 1/5 lysis buffer volume chloroform / isoamyl alcohol (24: 1).
- This mixture was mixed on the vortexer for 10 seconds and then tempered on ice for 10 minutes. The phases are separated by centrifugation at 15365 g and 4 ° C for
- RNA-MATRIX from the Rnaid TM plus kit (DIANOVA) added and incubated for 15 minutes at room temperature.
- the resulting RNA / RNA-MATRIX complex was pelleted by centrifugation at 7000 g and the supernatant was discarded.
- the pellet was then washed twice with 250 ml of RNA-WASH (DIANOVA) and dried after the last washing by vacuum centrifugation.
- the RNA was eluted by adding 20-30 ml of RNAse-free distilled water by tempering at 55 ° C for 15 minutes. After centrifugation at 7000 g and room temperature for 1 minute, the matrix was separated by transferring the RNA solution into a new tube.
- the quality of the RNA was checked by gel electrophoresis.
- the RNA was stored at -70 ° C.
- the cDNA was synthesized by reverse transcription of the mRNA using oligo (dT) primers as starter molecules for the polymerization. in the
- the following components were present in the synthesis approach: 200 ng-2 ⁇ g total RNA, 2 ⁇ l reverse transcriptase M-MLV (200 U / ⁇ l) (GIBCO / BRL), 8 ⁇ l of the associated 5xRT buffer (GIBCO / BRL), 1 ⁇ l DTT (0.1M) (GIBCO / BRL), 4 ⁇ l dNTP (2.5 mM) (SIGMA), 2 ⁇ l oligo (dT) 12-18 primer (100 ⁇ g / ml) (PROMEGA), 1 ⁇ l human pla zental RNAse Inhibitor (10000 U / ml) (GIBCO / BRL) and water ad 40 ⁇ l total volume.
- the mixture was tempered for 10 minutes at room temperature and then incubated at 37 ° C. for 45 minutes, subsequently heated to 95 ° C. for 3 minutes and immediately cooled on ice.
- the cDNA synthesized in this way was stored at -20 ° C.
- the amounts of the cDNAs were standardized using a "housekeeping" gene ( ⁇ -actin).
- the quantitative PCR was carried out using the ABI PRISM TM 7700 Sequence Detection System (PE Applied Biosystems). The following primers were used:
- ß-Actin sense 5'-TGG AAT CCT GTG GCA TCC ATG AAA C-3 ' antisense: 5'-TAA AAC GCA GCT CAG TAA CAG TCC G-3 '
- IFN- ⁇ sense 5'-AGCGGC TGA CTG AAC TCA GAT TGT AG-3 'antisense: 5 * -GTC ACA GTT TTC AGC TGT ATA GGG-3'
- TNF- ⁇ sense 5'-GGC AGG TCT ACT TTG GAG TCA TTG C-3 'antisense: 5'-ACA TTC GAG GCT CCA GTG AAT TCG G-3'
- IL-15 sense 5'-GCC AAC TGG ATA GAT GTA AGA TAT GAC CT-3 'antisense: 5'-CGT GTT GAT GAA CAT TTG GAC AAT GCG TAT-3'
- the DNA was amplified in 25 ul reaction volume (the reaction contained 1.4 mM of each dNTP, 4 mM MgCl 2 , 0.3 ⁇ mol of each primer and that
- Probe 2.5 ⁇ l 10-fold PCR buffer with SYBR Green [all PCR reagents came from the SYBR Green PCR core reagent kit; Perkin Elmer / Roche Molecular Systems Inc.] and 1.25 U Taq DNA polymerase and 0.25 U Amp Erase. After an initial denaturation step (95 ° C for 10 min), the samples were exposed to 40 cycles of denaturation (95 ° C for 30 s) and annealing / extension (60 ° C, 1.30 min).
- the products were analyzed using the ABI PRISM TM 7700 Sequence Detection System Standard Software. The statistical analysis of the results was carried out with the analysis of variance and post hoc comparison.
- interferon ⁇ is induced after treatment with Strain D 1701 or Strain NZ 2 6 and 12 hours after the application ( Figure 3). In Strain NZ 2, this induction is both significantly higher compared to placebo and to Strain D 1701. The level of interferon ⁇ expression observed after administration of D 1701 is not significant compared to placebo control. The values shown are those measured in cells obtained by peritoneal lavage.
- IL-15 is induced after treatment with Strain D 1701 or with Strain NZ 2 6 and 12 hours after the application ( Figure 5). This induction is 6 hours after application with Strain NZ 2 significantly higher than with Strain D 1701 or placebo. The level of IL-15 expression observed after administration of D 1701 is not significant compared to the placebo control. The values shown are those measured in cells obtained by peritoneal lavage.
- MDA-MB231 cells (ATCC # HTB26) were placed in complete medium (DMEM 88 5, FBS 10%, penicillin / streptomycin 1%, L-glutamine 1% while Gibco Life Technologies)) at 37 ° C and 5% CO 2 in an incubator cultured. On the day of the
- the cells were approximately 70% confluent. The cells were trypsinized, washed with HBSS, counted and adjusted to 2.5x10 7 cells / ml with precooled PBS.
- Female NCr nude mice (taconic) were used. The mice were between 8 and 10 weeks old and weighed approximately 22 g. All manipulations on the animals were carried out under sterile conditions.
- mice 5x10 6 cells in a total volume of 0.2 ml were injected subcutaneously into the flank region. The mice were then kept for a further seven days until the tumors reached an average mass of approximately 80 mg. The tumors were measured and the mice were randomly divided into three groups of ten animals each. The individual groups were administered as follows: Group 1 placebo (PBS) Group 2 parapoxvirus ovis, strain Dl 701 Group 3 parapoxvirus ovis, strain NZ2
- D1701 was at a dose of 2.5xl0 5 TCID 50 , NZ2 at a dose of lxlO 5
- TCID J0 administered a total of four times three days apart. The tumors were measured twice a week. Significance was determined using Student's test.
- Figure 6 shows the mean size of the tumors (in milligrams) in animals of the groups
- NK natural clientele
- Cytokines / chemokines conditional. With a complete and intact immune system, it would be assumed that the better effectiveness of NZ2 becomes even clearer.
- Adaptation to human cell lines is an important prerequisite for the production of viral strains on human cell lines.
- MRC-5 is suitable for the production of biological agents and vaccines.
- the strains were used with the same starting titer and the corresponding cell culture supernatants continued over 5 passages in MRC-5 cells.
- the titration of samples from the supernatants of the respectively infected MRC5 cells in TCID 50 is shown via the passenger number.
- FIG. 8 shows the virus titer in passenger experiments of DI 701 on bovine BK clone 3 a cells and on human WI-38 cells via the Number of passages. It can be seen that Dl 701 is still passable on BK clone 3a cells, but not on human WI-38 cells.
- mice Challenge tests have been performed on mice. Three groups of 10 test animals each were treated with lxlO 4 TCID 50 , 5xl0 4 TCID 50 and lxlO 5 TCID 50 , a control group received a placebo. The survival rate of the four test groups is shown in FIG. 10 over time after He ⁇ es virus infection. It was surprisingly found that NZ2 did not lose its immunostimulatory properties due to the passage on WI-38 cells.
- the therapeutic agent based on Parapoxvirus is applied systemically, for example intramuscularly, subcutaneously, intraperitoneally, intravenously, per os, or locally.
- the parapoxvirus is either purified and lyophilized and / or is suspended in a suitable solvent immediately before application or is in another suitable formulation or is in an enteric or other oral form of application.
- Suitable preparations can also be derived from offspring of NZ2 and the other strains or parts or fragments of NZ2 and the other strains or obtained by passage and / or adaptation to certain cells, for example WI-38, MRC-5 or Vero cells these descendants are made.
- vaccinia parts are to be understood as meaning expressed genomic or subgenomic fragments in suitable systems, for example fibroblast cell cultures. Fragments are understood to mean the fractions obtained by biochemical purification, for example chromatography, physically, for example by exposure to ultrasound, of disrupted particles.
- Intramuscular application of 10 6 to 10 7 TCID 50 Tissue Culture Infective Dosage for 4 weeks on every 3rd day followed by a 2 week break; repeated intramuscular application of 10 6 to 10 7 TCID 50 for 4 weeks on every 3rd
- TCID 50 of the formulation are applied subcutaneously in the abdominal area or intramuscularly in the area of the deltoid or quadriceps every 3rd day, a total of 5 times. Deviations from this scheme can be made according to the needs arising from the disease. The prophylaxis of colds is gargle and repeat this application daily as long as there is a risk of infection.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- AIDS & HIV (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (26)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020037000308A KR100805996B1 (ko) | 2000-07-11 | 2001-07-11 | 항-바이러스 의약 및 항암 의약을 제조하기 위한파라폭스바이러스 오비스 균주의 용도 |
GB0302630A GB2381454B8 (en) | 2000-07-11 | 2001-07-11 | Use of strains of Parapoxvirus ovis for producing antiviral medicaments and medicaments against cancer |
AU7063101A AU7063101A (en) | 2000-07-11 | 2001-07-11 | Use of strains of the parapox ovis virus for producing antiviral pharmaceuticalsand anticancer pharmaceuticals |
DE50109630T DE50109630D1 (de) | 2000-07-11 | 2001-07-11 | Verwendung von stämmen des parapoxvirus ovis zur herstellung von antiviralen arzneimitteln und arzneimitteln gegen krebs |
CA2415397A CA2415397C (en) | 2000-07-11 | 2001-07-11 | Use of strains of parapoxvirus ovis for producing antiviral medicaments and medicaments against cancer |
JP2002508456A JP5037775B2 (ja) | 2000-07-11 | 2001-07-11 | 抗ウイルス薬および癌に対する医薬の製造のためのパラポックスウイルスovisの使用 |
NZ523534A NZ523534A (en) | 2000-07-11 | 2001-07-11 | Use of strains of the parapox ovis virus for producing antiviral pharmaceuticals and anticancer pharmaceuticals |
LU90997A LU90997B1 (en) | 2000-07-11 | 2001-07-11 | Use of strains of the parapox ovis virus for producing antiviral pharmaceuticals ans anticancer pharmaceuticals |
EEP200300018A EE200300018A (et) | 2000-07-11 | 2001-07-11 | Parapoxvirus ovis tüvede kasutamine viirusvastaste ja vähivastaste ravimite valmistamiseks |
MXPA03000279A MXPA03000279A (es) | 2000-07-11 | 2001-07-11 | Uso de cepas del parapoxvirus ovis para la fabricacion de medicamentos antivirales y medicamentos contra el cancer. |
IL15364301A IL153643A0 (en) | 2000-07-11 | 2001-07-11 | Use of strains of the parapox ovis virus for producing antiviral pharmaceuticals and anticancer pharmaceuticals |
CN01812685.5A CN1455674B (zh) | 2000-07-11 | 2001-07-11 | 绵羊副痘病毒菌株用于制备抗病毒药物和抗癌药物的用途 |
EP01949489A EP1303286B1 (de) | 2000-07-11 | 2001-07-11 | Verwendung von stämmen des parapoxvirus ovis zur herstellung von antiviralen arzneimitteln und arzneimitteln gegen krebs |
SI200120048A SI21122A (sl) | 2000-07-11 | 2001-07-11 | Uporaba sevov parapoksvirusa ovis za proizvodnjo antivirusnih zdravil in zdravil proti raku |
HU0400479A HUP0400479A3 (en) | 2000-07-11 | 2001-07-11 | Use of strains of the parapox ovis virus for producing antiviral pharmaceuticals and anticancer pharmaceuticals |
BR0112407-2 BRPI0112407B8 (pt) | 2000-07-11 | 2001-07-11 | uso de cepas de parapoxvírus ovis para produzir medicamentos antivirais e medicamentos contra câncer |
SK36-2003A SK362003A3 (en) | 2000-07-11 | 2001-07-11 | Use of strains of the Parapox ovis virus for producing antiviral pharmaceuticals and anticancer pharmaceuticals |
AU2001270631A AU2001270631B2 (en) | 2000-07-11 | 2001-07-11 | Use of strains of the parapox ovis virus for producing antiviral pharmaceuticals and anticancer pharmaceuticals |
NO20030082A NO20030082D0 (no) | 2000-07-11 | 2003-01-08 | Anvendelse av stammer av parapox ovis virus for fremstilling av antivirusfarmasöytika og antikreftfarmasöytika |
BG107448A BG107448A (bg) | 2000-07-11 | 2003-01-08 | Използване щамове на parapoxvirus ovis за получаване на противовирусни лекарства и лекарства срещу рак |
FI20030037A FI20030037A (fi) | 2000-07-11 | 2003-01-10 | Parapoxvirus ovis-kantojen käyttö virusvastaisten lääkkeiden ja syövän vastaisten lääkkeiden tuottamiseksi |
SE0300034A SE0300034L (sv) | 2000-07-11 | 2003-01-10 | Användning av stammar av Parapoxvirus ovis för framställning av antivirala läkemedel och läkemedel mot cancer |
DK200300015A DK200300015A (da) | 2000-07-11 | 2003-01-10 | Anvendelse af stammer af Parapoxvirus ovis til fremstilling af antivirale lægemidler og lægemidler mod cancer |
HR20030096A HRP20030096A2 (en) | 2000-07-11 | 2003-02-10 | Use of strains of the parapox ovis virus for producing pharmacuticals and anticancer pharmaceuticals |
HK03106613.1A HK1054329B (zh) | 2000-07-11 | 2003-09-15 | 羊副痘病毒屬株在生產抗病毒藥物或者抗癌藥物中的應用 |
CY20061101024T CY1105408T1 (el) | 2000-07-11 | 2006-07-24 | Χρησιμοποιηση στελεχων του ιου parapox ovis για την παρασκευη αντιικων φαρμακων και φαρμακων κατα του καρκινου |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10033582.9 | 2000-07-11 | ||
DE10033582 | 2000-07-11 | ||
DE10122451.6 | 2001-05-09 | ||
DE10122451A DE10122451A1 (de) | 2000-07-11 | 2001-05-09 | Verwendung von Stämmen des Parapoxvirus ovis zur Herstellung von antiviralen Arzneimitteln und Arzneimitteln gegen Krebs |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002004002A2 true WO2002004002A2 (de) | 2002-01-17 |
WO2002004002A3 WO2002004002A3 (de) | 2002-10-31 |
Family
ID=26006335
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2001/007991 WO2002004002A2 (de) | 2000-07-11 | 2001-07-11 | Verwendung von stämmen des parapoxvirus ovis zur herstellung von antiviralen arzneimitteln und arzneimitteln gegen krebs |
Country Status (36)
Country | Link |
---|---|
US (1) | US6685950B2 (de) |
EP (1) | EP1303286B1 (de) |
JP (1) | JP5037775B2 (de) |
CN (1) | CN1455674B (de) |
AR (1) | AR029954A1 (de) |
AT (1) | ATE324115T1 (de) |
AU (2) | AU2001270631B2 (de) |
BG (1) | BG107448A (de) |
CA (1) | CA2415397C (de) |
CY (1) | CY1105408T1 (de) |
CZ (1) | CZ200371A3 (de) |
DE (1) | DE50109630D1 (de) |
DK (2) | DK1303286T3 (de) |
EE (1) | EE200300018A (de) |
ES (1) | ES2262663T3 (de) |
FI (1) | FI20030037A (de) |
GB (1) | GB2381454B8 (de) |
HK (1) | HK1054329B (de) |
HR (1) | HRP20030096A2 (de) |
HU (1) | HUP0400479A3 (de) |
IL (1) | IL153643A0 (de) |
LT (1) | LT5079B (de) |
LU (1) | LU90997B1 (de) |
LV (1) | LV12990B (de) |
MA (1) | MA26927A1 (de) |
MX (1) | MXPA03000279A (de) |
NO (1) | NO20030082D0 (de) |
NZ (1) | NZ523534A (de) |
PL (1) | PL366397A1 (de) |
PT (1) | PT1303286E (de) |
RU (1) | RU2003104525A (de) |
SE (1) | SE0300034L (de) |
SI (1) | SI21122A (de) |
SK (1) | SK362003A3 (de) |
UY (1) | UY26832A1 (de) |
WO (1) | WO2002004002A2 (de) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6844000B2 (en) | 2001-12-07 | 2005-01-18 | Bayer Pharmaceuticals Corporation | Use of Parapox B2L protein to treat cancer and modify immune responses |
WO2007059821A1 (en) * | 2005-11-24 | 2007-05-31 | Aicuris Gmbh & Co. Kg | Parapoxviruses in combination with classical cytotoxic chemotherapeutic agents as biochemotherapy for the treatment of cancer |
JP2009183297A (ja) * | 2009-03-31 | 2009-08-20 | Aicuris Gmbh & Co Kg | パラポックスウイルス・オヴィスの組換えタンパク質およびそれ由来の医薬組成物 |
JP2012115271A (ja) * | 2012-01-05 | 2012-06-21 | Aicuris Gmbh & Co Kg | パラポックスウイルス・オヴィスの組換えタンパク質およびそれ由来の医薬組成物 |
US8357363B2 (en) | 2001-06-13 | 2013-01-22 | Aicuris Gmbh & Co. Kg | Recombinant proteins of parapoxvirus ovis and pharmaceutical compositions therefrom |
CN111093697A (zh) * | 2017-09-07 | 2020-05-01 | 艾库里斯有限及两合公司 | 乙肝病毒(hbv)感染的个体的使用绵羊副痘病毒(ppvo)和至少一种另外的抗病毒药物的组合疗法 |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19922407A1 (de) * | 1999-05-14 | 2000-11-16 | Bayer Ag | Organ-, gewebs- und zellspezifisches Immuntherapeutikum für chronische virale Infektionen, sowie entzündliche, degenerative und proliferative Erkrankungen insbesondere der Leber sowie Krebs auf der Basis von rekombinantem Parapoxvirus |
US7097842B2 (en) * | 2000-11-23 | 2006-08-29 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
US7628980B2 (en) * | 2000-11-23 | 2009-12-08 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
AU2002231639B2 (en) | 2000-11-23 | 2007-01-04 | Bavarian Nordic A/S | Modified vaccinia ankara virus variant |
EP1420822B2 (de) * | 2002-04-19 | 2017-07-05 | Bavarian Nordic A/S | Modifizierte variante des vaccinia ankara virus als impfstoff für neugeborene |
KR101044538B1 (ko) * | 2002-09-05 | 2011-06-27 | 버베리안 노딕 에이/에스 | 무혈청 조건하에서 일차세포의 배양 및 바이러스의 증식방법 |
BRPI0513321B1 (pt) * | 2004-07-13 | 2022-03-08 | Aicuris Gmbh & Co. Kg | Vírus parapox em combinação com outros agentes antivirais para o tratamento de doenças virais |
NZ599677A (en) * | 2009-12-18 | 2014-10-31 | Bavarian Nordic As | Production of ifn-lambda by conventional dendritic cells and uses thereof |
WO2023083950A1 (en) * | 2021-11-10 | 2023-05-19 | Aicuris Gmbh & Co. Kg | Parapoxvirus for preparing for and treatment of respiratory virus infections in combination with immunomodulators |
WO2023083943A1 (en) * | 2021-11-10 | 2023-05-19 | Aicuris Gmbh & Co. Kg | Parapoxvirus for preparing for and treatment of respiratory virus infections in combination with antivirals |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3504940A1 (de) * | 1984-02-17 | 1985-10-31 | Mayr, Anton, Prof. Dr.med.vet. Dr.h.c.mult., 8000 München | Multipotente paramunitaetsmediatoren, verfahren zu ihrer herstellung und diese mediatoren enthaltende arzneimittel |
WO1995022978A1 (en) * | 1994-02-23 | 1995-08-31 | Anton Mayr | Paramunity inducer based on combinations of poxvirus components, process to prepare it and its use as medicament |
WO1997038724A1 (de) * | 1996-04-15 | 1997-10-23 | Anton Mayr | Neue indikationen für die verwendung von multipotenten paramunitätsinducern aus attenuierten, nicht-immunogenen pockenviren oder parapockenviren als arzneimittel |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2714665A1 (de) * | 1977-04-01 | 1978-10-05 | Mayr Anton | Praeparat zur behandlung von herpes zoster und anderen herpes-infektionen, sowie verfahren zu seiner herstellung |
US5443964A (en) * | 1987-08-10 | 1995-08-22 | Duke University | Poxvirus insertion/expression vector |
US5648101A (en) * | 1994-11-14 | 1997-07-15 | Tawashi; Rashad | Drug delivery of nitric oxide |
BR9707785A (pt) * | 1996-02-28 | 1999-07-27 | Bayer Ag | Parapoxvírus que contém dna estrangeiro preparação dos mesmos e uso dos mesmos em vacinas |
IL126349A0 (en) * | 1996-03-29 | 1999-05-09 | Univ Otago | Parapoxvirus vectors |
SE9700617D0 (sv) * | 1997-02-21 | 1997-02-21 | Kjell Alving | New composition |
DE19843222A1 (de) * | 1998-09-22 | 2000-03-30 | Hassan Jomaa | Verwendung von phosphororganischen Verbindungen zur therapeutischen und prophylaktischen Behandlung von Infektionen |
NZ511119A (en) * | 1998-11-02 | 2004-04-30 | Ludwig Inst Cancer Res | Vascular endothelial growth factor-like protein from ORF virus NZ2 binds and activates mammalian VEGF receptor-2 |
-
2001
- 2001-07-11 EP EP01949489A patent/EP1303286B1/de not_active Expired - Lifetime
- 2001-07-11 MX MXPA03000279A patent/MXPA03000279A/es unknown
- 2001-07-11 ES ES01949489T patent/ES2262663T3/es not_active Expired - Lifetime
- 2001-07-11 AT AT01949489T patent/ATE324115T1/de active
- 2001-07-11 CZ CZ200371A patent/CZ200371A3/cs unknown
- 2001-07-11 WO PCT/EP2001/007991 patent/WO2002004002A2/de active IP Right Grant
- 2001-07-11 SK SK36-2003A patent/SK362003A3/sk not_active Application Discontinuation
- 2001-07-11 SI SI200120048A patent/SI21122A/sl not_active IP Right Cessation
- 2001-07-11 PL PL01366397A patent/PL366397A1/xx not_active Application Discontinuation
- 2001-07-11 JP JP2002508456A patent/JP5037775B2/ja not_active Expired - Lifetime
- 2001-07-11 CN CN01812685.5A patent/CN1455674B/zh not_active Expired - Lifetime
- 2001-07-11 DK DK01949489T patent/DK1303286T3/da active
- 2001-07-11 NZ NZ523534A patent/NZ523534A/en not_active IP Right Cessation
- 2001-07-11 IL IL15364301A patent/IL153643A0/xx active IP Right Grant
- 2001-07-11 EE EEP200300018A patent/EE200300018A/xx unknown
- 2001-07-11 AU AU2001270631A patent/AU2001270631B2/en not_active Expired - Fee Related
- 2001-07-11 DE DE50109630T patent/DE50109630D1/de not_active Expired - Lifetime
- 2001-07-11 UY UY26832A patent/UY26832A1/es not_active Application Discontinuation
- 2001-07-11 RU RU2003104525/15A patent/RU2003104525A/ru not_active Application Discontinuation
- 2001-07-11 AR ARP010103292A patent/AR029954A1/es unknown
- 2001-07-11 AU AU7063101A patent/AU7063101A/xx active Pending
- 2001-07-11 CA CA2415397A patent/CA2415397C/en not_active Expired - Lifetime
- 2001-07-11 PT PT01949489T patent/PT1303286E/pt unknown
- 2001-07-11 LU LU90997A patent/LU90997B1/en active
- 2001-07-11 US US09/903,013 patent/US6685950B2/en not_active Expired - Lifetime
- 2001-07-11 HU HU0400479A patent/HUP0400479A3/hu unknown
- 2001-07-11 GB GB0302630A patent/GB2381454B8/en not_active Expired - Fee Related
-
2003
- 2003-01-08 NO NO20030082A patent/NO20030082D0/no unknown
- 2003-01-08 BG BG107448A patent/BG107448A/bg unknown
- 2003-01-10 SE SE0300034A patent/SE0300034L/xx not_active Application Discontinuation
- 2003-01-10 MA MA26994A patent/MA26927A1/fr unknown
- 2003-01-10 FI FI20030037A patent/FI20030037A/fi not_active IP Right Cessation
- 2003-01-10 DK DK200300015A patent/DK200300015A/da not_active Application Discontinuation
- 2003-02-03 LT LT2003009A patent/LT5079B/lt not_active IP Right Cessation
- 2003-02-10 HR HR20030096A patent/HRP20030096A2/xx not_active Application Discontinuation
- 2003-02-11 LV LVP-03-14A patent/LV12990B/lv unknown
- 2003-09-15 HK HK03106613.1A patent/HK1054329B/zh not_active IP Right Cessation
-
2006
- 2006-07-24 CY CY20061101024T patent/CY1105408T1/el unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3504940A1 (de) * | 1984-02-17 | 1985-10-31 | Mayr, Anton, Prof. Dr.med.vet. Dr.h.c.mult., 8000 München | Multipotente paramunitaetsmediatoren, verfahren zu ihrer herstellung und diese mediatoren enthaltende arzneimittel |
WO1995022978A1 (en) * | 1994-02-23 | 1995-08-31 | Anton Mayr | Paramunity inducer based on combinations of poxvirus components, process to prepare it and its use as medicament |
WO1997038724A1 (de) * | 1996-04-15 | 1997-10-23 | Anton Mayr | Neue indikationen für die verwendung von multipotenten paramunitätsinducern aus attenuierten, nicht-immunogenen pockenviren oder parapockenviren als arzneimittel |
Non-Patent Citations (1)
Title |
---|
RZIHA H-J ET AL: "Parapoxviruses: potential alternative vectors for directing the immune response in permissive and non-permissive hosts" JOURNAL OF BIOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, Bd. 73, Nr. 2-3, 20. August 1999 (1999-08-20), Seiten 235-242, XP004180185 ISSN: 0168-1656 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8357363B2 (en) | 2001-06-13 | 2013-01-22 | Aicuris Gmbh & Co. Kg | Recombinant proteins of parapoxvirus ovis and pharmaceutical compositions therefrom |
US8852577B2 (en) | 2001-06-13 | 2014-10-07 | Aicuris Gmbh & Co. Kg | Recombinant proteins of Parapoxvirus ovis and pharmaceutical compositions therefrom |
US9714272B2 (en) | 2001-06-13 | 2017-07-25 | Aicuris Gmbh & Co. Kg | Recombinant proteins of parapdxvirus ovis and pharmaceutical compositions therefrom |
US6844000B2 (en) | 2001-12-07 | 2005-01-18 | Bayer Pharmaceuticals Corporation | Use of Parapox B2L protein to treat cancer and modify immune responses |
WO2007059821A1 (en) * | 2005-11-24 | 2007-05-31 | Aicuris Gmbh & Co. Kg | Parapoxviruses in combination with classical cytotoxic chemotherapeutic agents as biochemotherapy for the treatment of cancer |
US7897159B2 (en) | 2005-11-24 | 2011-03-01 | Aicuris Gmbh & Co. Kg | Parapoxviruses in combination with classical cytotoxic chemotherapeutic agents as biochemotherapy for the treatment of cancer |
JP2009183297A (ja) * | 2009-03-31 | 2009-08-20 | Aicuris Gmbh & Co Kg | パラポックスウイルス・オヴィスの組換えタンパク質およびそれ由来の医薬組成物 |
JP2012115271A (ja) * | 2012-01-05 | 2012-06-21 | Aicuris Gmbh & Co Kg | パラポックスウイルス・オヴィスの組換えタンパク質およびそれ由来の医薬組成物 |
CN111093697A (zh) * | 2017-09-07 | 2020-05-01 | 艾库里斯有限及两合公司 | 乙肝病毒(hbv)感染的个体的使用绵羊副痘病毒(ppvo)和至少一种另外的抗病毒药物的组合疗法 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1303286B1 (de) | Verwendung von stämmen des parapoxvirus ovis zur herstellung von antiviralen arzneimitteln und arzneimitteln gegen krebs | |
Song et al. | The antiviral effects of acteoside and the underlying IFN-γ-inducing action | |
Varanasi et al. | Azacytidine treatment inhibits the progression of herpes stromal keratitis by enhancing regulatory T cell function | |
DE10122451A1 (de) | Verwendung von Stämmen des Parapoxvirus ovis zur Herstellung von antiviralen Arzneimitteln und Arzneimitteln gegen Krebs | |
WO2016127848A1 (zh) | 绿原酸在制备预防和治疗原发性皮肤t细胞淋巴癌的药物中的用途 | |
CA2251690C (en) | New indications for the use as medicaments of multipotent parapox immunity inducers from attenuated, non-immunogenic pox viruses or parapox viruses | |
DE19922407A1 (de) | Organ-, gewebs- und zellspezifisches Immuntherapeutikum für chronische virale Infektionen, sowie entzündliche, degenerative und proliferative Erkrankungen insbesondere der Leber sowie Krebs auf der Basis von rekombinantem Parapoxvirus | |
US20170348393A1 (en) | Treatment of cns inflammatory disorders | |
CN110075131B (zh) | 寨卡病毒减毒株在治疗脑胶质瘤中的应用 | |
CN111214472B (zh) | 依诺沙星在制备预防和/或治疗黄病毒感染的药物中的应用 | |
CN116459295B (zh) | 一种肺炎清化方及其应用 | |
CN114917228B (zh) | 一种用于预防性治疗狂犬病的药方及其制备方法与应用 | |
EP1289548B1 (de) | Mittel zur stimulation des immunsystems | |
CN116459295A (zh) | 一种肺炎清化方及其应用 | |
CN106581052A (zh) | 柠檬酸根离子和铁离子在抑制rna病毒中的应用 | |
Martino et al. | Treatment of Hepatic Abcesses in Chronic Granulomatous Disease with Granulomatous Disease with... | |
CN103933578A (zh) | miRNA-185的应用和含有其的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
ENP | Entry into the national phase |
Ref document number: 0302630 Country of ref document: GB Kind code of ref document: A Free format text: PCT FILING DATE = 20010711 |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001949489 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 153643 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11/MUMNP/2003 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001270631 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 523534 Country of ref document: NZ Ref document number: 2415397 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2003/000279 Country of ref document: MX Ref document number: PV2003-71 Country of ref document: CZ Ref document number: 1020037000308 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2003 200300018 Country of ref document: RO Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003/00274 Country of ref document: ZA Ref document number: 362003 Country of ref document: SK Ref document number: 091542001 Country of ref document: AT Ref document number: 200300274 Country of ref document: ZA Ref document number: 20030037 Country of ref document: FI |
|
ENP | Entry into the national phase |
Ref document number: 200350004 Country of ref document: ES Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: P200350004 Country of ref document: ES Ref document number: 018126855 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: A9154/2001 Country of ref document: AT |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003009 Country of ref document: LT |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200120048 Country of ref document: SI |
|
WWE | Wipo information: entry into national phase |
Ref document number: 0302630.9 Country of ref document: GB |
|
WWE | Wipo information: entry into national phase |
Ref document number: P20030096A Country of ref document: HR |
|
ENP | Entry into the national phase |
Ref document number: 2003104525 Country of ref document: RU Kind code of ref document: A Ref country code: RU Ref document number: RU A |
|
WWP | Wipo information: published in national office |
Ref document number: 1020037000308 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: PV2003-71 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 2001949489 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003009 Country of ref document: LT |
|
WWG | Wipo information: grant in national office |
Ref document number: 2003009 Country of ref document: LT |
|
REG | Reference to national code |
Ref country code: PT Ref legal event code: FG4A Effective date: 20040812 |
|
WWP | Wipo information: published in national office |
Ref document number: 523534 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 523534 Country of ref document: NZ |
|
WWR | Wipo information: refused in national office |
Ref document number: 200350004 Country of ref document: ES Kind code of ref document: A |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001949489 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: PT Ref legal event code: MM4A Free format text: LAPSE DUE TO NON-PAYMENT OF FEES Effective date: 20070111 |